Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.83 |
| ▸ | FAAH | O00519 | 4/20 | 0.78 |
| ▸ | NAAA | Q02083 | 1/20 | 0.77 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.72 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.69 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.67 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.64 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL819566 | 1.00 | CASP2 (0.83) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL10790501 | 1.00 | CASP2 (0.83) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL22271678 | 1.00 | CASP2 (0.83) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL2150966 | 1.00 | CASP2 (0.83) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL8368632 | 1.00 | CASP2 (0.83) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL498043 | 1.00 | CASP2 (0.83) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL23775006 | 1.00 | CASP2 (0.83) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL21234011 | 1.00 | CASP2 (0.83) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL20542645 | 1.00 | CASP2 (0.83) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL21633848 | 1.00 | CASP2 (0.83) | CASP2FAAHNAAADNM1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3470391-A1 | COSMETIC BASE INCLUDING AMIDE ALCOHOL ESTER, AND COSMETIC | Kokyu Alcohol Kogyo Co., Ltd. (JP) | 2019-04-17 | — | — | EP | disclosed |
| US-10017527-B2 | KLK4 inhibitors | UNIVERSITEIT ANTWERPEN (BE) | 2018-07-10 | — | — | US | disclosed |
| US-20170101427-A1 | NOVEL KLK4 INHIBITORS | UNIVERSITEIT ANTWERPEN (BE) | 2017-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017527-B2 | KLK4 inhibitors | KLK4, KLK3, KLK1 | CASP2 1670/4885FAAH 4571/4885NAAA 2007/4885 |
| US-20170101427-A1 | NOVEL KLK4 INHIBITORS | KLK4, KLK3, KLK1 | CASP2 1531/4885FAAH 4623/4885NAAA 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.